Galectin 3‐binding protein (LGALS3BP) depletion attenuates hepatic fibrosis by reducing transforming growth factor‐β1 (TGF‐β1) availability and inhibits hepatocarcinogenesis

Abstract Background Increased Galectin 3‐binding protein (LGALS3BP) serum levels have been used to assess hepatic fibrosis stages and the severity of hepatocellular carcinoma (HCC). Considering the crucial role of transforming growth factor‐β1 (TGF‐β1) in the emergence of these diseases, the present...

Full description

Bibliographic Details
Main Authors: Dae‐Hwan Kim, Minjeong Sung, Myong‐Suk Park, Eun‐Gene Sun, Sumin Yoon, Kyung Hyun Yoo, Kamalakannan Radhakrishnan, Sung Yun Jung, Woo‐Kyun Bae, Sang‐Hee Cho, Ik‐Joo Chung
Format: Article
Language:English
Published: Wiley 2024-10-01
Series:Cancer Communications
Subjects:
Online Access:https://doi.org/10.1002/cac2.12600